Dysfunctional CD8+ T cells in the tumor microenvironment are associated with response to nivolumab in mismatch repair deficient (dMMR) or hypermutated ovarian (OVCA) or endometrial cancer (EC).

Claire Frances Friedman Memorial Sloan Kettering Cancer Center and Weill Medical College at Cornell University, New York, NY info_outline Claire Frances Friedman, Qin Zhou, Alexia Iasonos, Aliya Holland, Lizbeth Ramirez, Rachel N. Grisham, Robin Guo, Stuart M. Lichtman, Chrisann Kyi, Vicky Makker, Jennifer Jean Mueller, Roisin Eilish O'Cearbhaill, Alison M. Schram, William P. Tew, Jason A. Konner, Tiffany A. Troso-Sandoval, Andreas Georg Wibmer, Carol Aghajanian, Martee Leigh Hensley, Dmitriy Zamarin

Authors Claire Frances Friedman Memorial Sloan Kettering Cancer Center and Weill Medical College at Cornell University, New York, NY info_outline Claire Frances Friedman, Qin Zhou, Alexia Iasonos, Aliya Holland, Lizbeth Ramirez, Rachel N. Grisham, Robin Guo, Stuart M. Lichtman, Chrisann Kyi, Vicky Makker, Jennifer Jean Mueller, Roisin Eilish O'Cearbhaill, Alison M. Schram, William P. Tew, Jason A. Konner, Tiffany A. Troso-Sandoval, Andreas Georg Wibmer, Carol Aghajanian, Martee Leigh Hensley, Dmitriy Zamarin Organizations Memorial Sloan Kettering Cancer Center and Weill Medical College at Cornell University, New York, NY, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, Memorial Sloan Kettering Cancer Center, New York, NY, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, Memorial Sloan-Kettering Cancer Center, New York, NY, Memorial Sloan Kettering Monmouth, Middletown, NJ, Memorial Sloan Kettering Cancer Center and Weil Cornell Medical College, New York, NY Abstract Disclosures Research Funding Other Foundation Pharmaceutical/Biotech Company Background: EC and a subset of OVCA are associated with high rates of dMMR and are responsive to PD-1 blockade. It is unknown what additional biomarkers beyond dMMR may enrich for benefit in these patients (pts). Methods: This was an investigator-initiated, single-arm, phase II study. Eligible pts had recurrent EC or OVCA that met one of the following criteria: 1) dMMR, as determined by immunohistochemical loss of expression of 1+ MMR genes; 2) MSI-H, as determined by next generation sequencing (MSK-IMPACT); or 3) hypermutated, defined as 20+ non-synonymous somatic mutations. Pts received nivo 240mg IV every 2 weeks or 480mg IV every 4 weeks until toxicity or progression. The co-primary endpoints were 1) the progression-free survival (PFS) rate at 24 weeks (PFS24) and 2) the objective response rate (ORR) by RECIST v1.1. The study was designed using Simon’s two-stage design, with a sample size of 40 pts based on a promising ORR of 25% with a type I error rate of 0.025 and a type II error rate of 0.05. Overall survival (OS), PFS and duration of response (DOR) were calculated using the method of Kaplan-Meier. Adverse events (AEs) were graded per CTCAE and tabulated. Biomarker analyses on the available archival tissue were performed using multiplex immunofluorescence (mIF) labeling for CD8, PD-1, TOX, PD-1, PD-L1, and FoxP3. Quantification of immune phenotypes and interaction studies between CD8+ T cells and PD-L1+ cells was performed in HALO. Results: Between 9/2017 and 5/2021, 35 pts were enrolled; the study closed early due to slow accrual. The median duration of follow-up was 33.2 months. The median age was 64 years (range 36-87); 82% of pts were white, 54% had high grade EC, and 65% had confirmed MLH1 hypermethylation. The ORR was 57.1% (97.5% CI 39.4-100%) [37% PR, 20% CR]. The PFS24 was 62.9% and median PFS was 26.7 months (95% CI 4.9-NE). Neither median DOR nor OS was reached. OS at 1 year was 76.4% (95% CI 58.2-87.4%). The ORR in patients with MLH1 hypermethylation was 52%; 4 of 5 patients with confirmed germline MMR alterations had a response by RECIST. AEs were consistent with the reported literature. Notable treatment related AEs included Grade 4 myocarditis with associated grade 4 AV block, grade 2 extraocular paresis, grade 3 Type 1 diabetes mellitus, and grade 3 elevations in AST/ALT. On mIF analysis, PD-L1 expression did not distinguish responders from non-responders, though interaction between CD8 + T cells and PD-L1 + cells was associated with CR/PR. Increase in relative fraction of dysfunctional CD8 + T cells (characterized by CD8 + TOX + PD-1 + phenotype) was also associated with CR/PR. Conclusions: Nivo is an effective and tolerable treatment option for patients with MMR-D/MSI-H or hypermutated EC or OVCA. Presence of dysfunctional CD8 + T cells in the tumors was associated with response, while expression of PD-L1 was not predictive. Clinical trial information: NCT03241745.